Head-to-head · WeighScore
Basal Health vs Framework
The verdict
Framework takes it — 51.6/100 to 47.7/100.
Framework grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Framework is a personalised-plan GLP-1 telehealth platform offering compounded semaglutide and tirzepatide with doctor-guided treatment selection and a named pharmacy partner.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Basal Health | Framework |
|---|---|---|
| WeighScore | 47.7/100 | 51.6/100 |
| Grade | C | C |
| Scorecard rank | #494 | #485 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #494 · C
Strengths
- Stated nationwide coverage (50 states + DC)
- Metabolic-framework positioning rather than single-product
- Clinician-supervised dosing rather than a fixed protocol
- Adaptive monitoring approach
Where it loses points
- No pricing shown publicly — you must complete intake to see cost
- Compounding pharmacy partner not named
- GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
- No LegitScript badge visible on the homepage
- No FDA compounded-medication disclaimer on the pages reviewed
Graded #485 · C
Strengths
- The compounding pharmacy partner is named, which most of this field does not do
- Treatment selection is doctor-guided rather than a fixed product menu
- US-licensed clinicians and a 503A pharmacy pathway
Where it loses points
- No monthly medication price is published: the tirzepatide and semaglutide pages carry no price at all, and the homepage advertises a per-week figure for 'GLP-1s' generally rather than a rate for either drug
- The only drug-specific prices anywhere on the site sit on a legacy page — semaglutide at $349 per three months and tirzepatide at $549 per three months
- A '$75/month with 3-month package' figure is footnoted as a promotion for new GLP-1 users only
- Different landing pages advertise different per-week rates, $25 on one and $19 on another
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.